Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2001-08-14 Earnings Release
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys AG english
Earnings Release Classification · 100% confidence The document is explicitly titled 'Ad hoc announcement' and reports 'financial results for its second quarter and six months ended June 30, 2001.' It provides key financial figures (revenues, net loss) and operational highlights for the period. This structure—a brief announcement summarizing key financial performance metrics for a specific period (quarterly)—aligns perfectly with the definition of an Earnings Release (ER). It is not the comprehensive report (IR) but the initial summary announcement. H1 2001
2001-08-14 English
MorphoSys AG deutsch
Regulatory Filings Classification · 95% confidence The document is a short announcement (1755 characters) dated July 30, 2001, labeled as 'Ad-hoc'. It details a specific operational achievement—reaching a preclinical milestone in a cooperation with GPC Biotech regarding an antibody program for transplant rejection and GvHD. It mentions receiving a milestone payment but does not contain comprehensive financial statements, management discussions, or formal voting results. Since it is a specific, non-standard operational update that doesn't fit the definitions for ER, IR, 10-K, or CT, and it is an announcement rather than a full report, it best fits the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes like DIRS or DIV. Given its nature as a time-sensitive, non-periodic operational update, RNS is the most appropriate classification.
2001-07-30 German
MorphoSys AG english
Regulatory Filings Classification · 99% confidence The document is a short 'Ad hoc announcement' dated July 30, 2001, detailing a specific operational update regarding a milestone achievement in a collaboration between MorphoSys and GPC Biotech concerning an immunology antibody program. It is not a comprehensive financial report (like 10-K or IR), nor is it a standard earnings release (ER). It announces a specific business development event (collaboration milestone/payment). Since it is a short, specific, non-financial regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory news releases.
2001-07-30 English
MorphoSys AG english
Regulatory Filings Classification · 99% confidence The document is a short announcement labeled 'Ad-hoc' dated July 24, 2001. It details a specific business development: the discovery of a novel antibody therapeutic resulting from a collaboration between MorphoSys AG and ProChon Biotech. It is not a full financial report (like 10-K or IR), a management change announcement (MANG), or a dividend notice (DIV). It describes a specific corporate event/development that doesn't fit neatly into the primary financial reporting categories. Since it is a specific, non-standard corporate update that doesn't match the definitions for LTR (Legal), TAR (M&A), CAP (Financing), or DIRS (Insider Trading), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements not covered elsewhere.
2001-07-24 English
MorphoSys AG deutsch
Regulatory Filings Classification · 99% confidence The document is labeled as an 'Ad-hoc-Mitteilung' (Ad-hoc announcement) dated July 24, 2001. It details a specific business development: the discovery of a new class of antibody drug candidates resulting from a collaboration between MorphoSys AG and ProChon Biotech Ltd. This type of announcement, focusing on a significant, non-periodic business event (like a discovery, partnership milestone, or legal update), typically falls under general regulatory announcements or specific event disclosures. Since it is not a formal financial report (10-K, IR, ER), a management change (MANG), or a director's dealing (DIRS), and it announces a specific business development rather than a report publication (RPA), the most appropriate general category for significant, non-standard corporate news that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous regulatory disclosures. Given the content is a specific business development announcement (drug discovery milestone), it is a significant event disclosure. While 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are specific, this is about R&D success. 'RNS' is the best fit as a general regulatory announcement category for such news.
2001-07-24 German
MorphoSys AG english
Regulatory Filings Classification · 99% confidence The document is a short announcement (1511 characters) dated July 19, 2001, labeled as 'Ad-hoc'. It details a specific operational achievement: a milestone reached in a collaboration with GPC Biotech regarding an antibody program for cancer treatment, triggering an undisclosed payment. This is not a standard periodic financial report (like 10-K or IR), nor is it a management change, dividend announcement, or proxy material. It is a specific, material, non-financial operational update that is not covered by the more specific categories like ER, CAP, or LTR. Given the nature of reporting specific operational progress that might impact the company's future value but doesn't fit neatly into the primary financial or governance categories, and considering it is a brief, immediate announcement, it best fits the general 'Regulatory Filings' fallback category (RNS) for miscellaneous material news, as it is an 'Ad hoc announcement' transmitted by DGAP.
2001-07-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.